MARKET

CHEK

CHEK

Check Cap
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3639
+0.0250
+7.38%
After Hours: 0.3657 +0.0018 +0.49% 17:49 05/27 EDT
OPEN
0.3390
PREV CLOSE
0.3389
HIGH
0.3700
LOW
0.3380
VOLUME
588.98K
TURNOVER
0
52 WEEK HIGH
1.909
52 WEEK LOW
0.3000
MARKET CAP
42.36M
P/E (TTM)
-1.7411
1D
5D
1M
3M
1Y
5Y
Check-Cap Announces Initiation of the U.S. Pivotal Trial
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before th...
PR Newswire · 05/11 12:00
Check-Cap GAAP EPS of -$0.21 misses by $0.16
Check-Cap press release (NASDAQ:CHEK): Q4 GAAP EPS of -$0.21 misses by $0.16. Cash and cash equivalents, restricted cash and short-term bank deposits as of December 31, 2021 were $51.9M.
Seekingalpha · 04/07 12:49
Check-Cap Reports Fourth Quarter and Full Year 2021 Financial Results
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before t...
PR Newswire · 04/07 12:30
Check Cap stock slumps on $10M equity offering
Check Cap (NASDAQ:CHEK) has slumped ~34% pre-market after the medical diagnostics firm announced a $10M equity offering. The offering comprises 20M of the company's ordinary shares and accompanying warrants to purchase up
Seekingalpha · 03/01 13:50
Check-Cap Ltd. Announces $10M Registered Direct Offering
ISFIYA, Israel, March 1, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company
Benzinga · 03/01 13:32
Check-Cap Ltd. Announces $10 Million Registered Direct Offering
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test, to detect polyps before ...
PR Newswire · 03/01 13:30
FDA Gives Green To Check-Cap's Pivotal Study For Capsule-Based Colorectal Cancer Screening Test
The FDA has approved Check-Cap Ltd's (NASDAQ:
Benzinga · 02/07 15:19
Check-Cap gets FDA OK to start pivotal trial for cancer screening test
Check-Cap (NASDAQ:CHEK) plans to start the U.S. pivotal study for its C-Scan cancer screening test after the FDA approved its amended Investigational Device Exemption (IDE) application, the company announced on
Seekingalpha · 02/07 13:56
More
No Data
Learn about the latest financial forecast of CHEK. Analyze the recent business situations of Check Cap through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CHEK stock price target is 2.000 with a high estimate of 3.000 and a low estimate of 1.000.
High3.000
Average2.000
Low1.000
Current 0.3639
EPS
Actual
Estimate
-0.05-0.04-0.02-0.01
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 37
Institutional Holdings: 1.77M
% Owned: 1.52%
Shares Outstanding: 116.41M
TypeInstitutionsShares
Increased
6
215.48K
New
6
1.01M
Decreased
1
30.67K
Sold Out
6
4.20M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Director
Steven Hanley
Chief Executive Officer
Alex Ovadia
Chief Financial Officer
Mira Rosenzweig
Chief Technology Officer
Yoav Kimchy
Vice President - Operations
Joshua Belkar
Vice President
Hanit Brenner-lavie
Vice President
Israel Hershko
Vice President - Research & Development
Boaz Shpigelman
Independent Director
Clara Ezed
Independent Director
Mary Jo Gorman
Independent Director
XiangQian Lin
Independent Director
Yuval Yanai
No Data
No Data
About CHEK
Check-Cap is a Israel-based clinical-stage medical diagnostics company developing. The Company develops C-Scan, capsule-based, system ingestible imaging for colorectal cancer screening.

Webull offers kinds of Check Cap Ltd stock information, including NASDAQ:CHEK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHEK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CHEK stock methods without spending real money on the virtual paper trading platform.